{"result": "(\"entity\"<|>PACIENTE<|>PERSON<|>Patients receiving parenteral nutrition (NP) require careful selection to avoid complications and ensure effective treatment.)\n##\n(\"entity\"<|>HÍGADO<|>GEO<|>The liver is an organ that may require transplantation in patients with severe liver disease related to parenteral nutrition.)\n##\n(\"entity\"<|>INTESTINO DELGADO<|>GEO<|>The small intestine is another organ that may be considered for transplantation in patients with intestinal failure.)\n##\n(\"entity\"<|>NUTRICIÓN PARENTERAL TOTAL<|>EVENT<|>Total parenteral nutrition (TPN) is a method of delivering all nutritional requirements intravenously, crucial for patients unable to eat.)\n##\n(\"entity\"<|>CIRROSIS HEPÁTICA<|>EVENT<|>Liver cirrhosis is a condition that may necessitate liver transplantation in patients receiving parenteral nutrition.)\n##\n(\"entity\"<|>HIPERTENSIÓN PORTAL<|>EVENT<|>Portal hypertension is a condition that may lead to the consideration of transplantation in patients with liver disease.)\n##\n(\"relationship\"<|>PACIENTE<|>NUTRICIÓN PARENTERAL<|>Patients are the recipients of parenteral nutrition, which is essential for their treatment<|>10)\n##\n(\"relationship\"<|>HÍGADO<|>NUTRICIÓN PARENTERAL<|>The liver may be affected by complications arising from parenteral nutrition, leading to potential transplantation<|>6)\n##\n(\"relationship\"<|>INTESTINO DELGADO<|>NUTRICIÓN PARENTERAL<|>The small intestine may also be impacted by parenteral nutrition, with transplantation being a consideration for severe cases<|>6)\n##\n(\"relationship\"<|>NUTRICIÓN PARENTERAL TOTAL<|>NUTRICIÓN PARENTERAL<|>Total parenteral nutrition is a comprehensive form of parenteral nutrition that meets all nutritional needs<|>9)\n##\n(\"relationship\"<|>CIRROSIS HEPÁTICA<|>NUTRICIÓN PARENTERAL<|>Cirrhosis may develop in patients receiving parenteral nutrition, leading to complications<|>7)\n##\n(\"relationship\"<|>HIPERTENSIÓN PORTAL<|>NUTRICIÓN PARENTERAL<|>Portal hypertension can arise as a complication in patients on parenteral nutrition, influencing treatment decisions<|>5)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: se debe valorar el aporte de EL enriquecidas en AGW3, ya que los estudios en ese tipo de paciente reflejan una eficacia en la prevención y reversión de la enfermedad hepática asociada a la NP79-81.\n- Tratamiento del sobrecrecimiento bacteriano: Tratamiento empírico con metronidazol, dirigido a las bacterias anaerobias de la flora colónica.\n- Tratamiento con ácido ursodesoxicólico en pacientes con hepatopatía en pacientes con NP, pueden disminuir la ictericia y la hepatoesplenomegalia, por un aumento del pool de ácidos biliares hidrofílicos no hepatotóxicos, aunque son muy escasos los estudios en pacientes con NP74.\n- Prevención y tratamiento de procesos infecciosos.\n- Trasplante de intestino delgado y/o hígado: Se debe indicar en pacientes muy seleccionados,\n\npresenta una alta mortalidad (menor si solo es trasplante intestinal aislado sin hepatopatía no evolucionada). Las unidades de trasplante del Reino Unido sugieren considerar la posibilidad de trasplante solo si hay hipertensión portal, cirrosis hepática o fibrosis82.\n\n7.6. Enfermedad metabólica ósea\n\nLa enfermedad metabólica ósea (EMO) se ha observado en regímenes de nutrición parenteral muy prolongados. En un estudio transversal se observó osteoporosis en el 42% de los pacientes y osteopenia en el 84% de los pacientes con NPD83. En otro trabajo español se detectó afectación ósea en el 52% al inicio de la NP y en un 81% de los pacientes después de 6 años con NP84.\n\nNo está claro el papel que juega la NPD en la pérdida de masa ósea, y cada vez existe más consenso en reconocer que la EMO tiene un origen multifactorial dependiendo, en gran medida, de la enfermedad subyacente que origina la insuficiencia intestinal.\n\nAdemás de los factores de riesgo tradicionales para la aparición de osteoporosis (sexo femenino, menopausia, edad avanzada, bajo peso, consumo de tabaco y alcohol, inactividad física y ciertos fármacos), se pueden añadir otros relacionados con la NPD como la toxicidad del aluminio de la NP, disminución de los niveles de PTH (por un incremento de la sensibilidad de la vitamina D), aporte deficitario de vitamina D, y la hipercalciuria inducida por la infusión endovenosa de nutrientes83, 85.\n\n- Manejo de la EMO:\n\n  - Densitometría mineral ósea al inicio, y anualmente, durante el período con NP85.\n  - Adecuado aporte de calcio (15 mEq/día) con una ratio calcio/fosfato correcta66.\n  - Suplementación con vitamina D en los pacientes con niveles de PTH elevados83.\n  - El uso de bifosfonatos en pacientes con osteopenia, podría suponer una disminución de los marcadores de resorción ósea86.\n\n7.7. Complicaciones relacionadas con el catéter (se analizan en el tema 48)\n\n- Complicaciones mecánicas.\n- Complicaciones infecciosas.\n\n8. Resumen\n\nLa NP es vital en muchos pacientes con insuficiencia intestinal. Seleccionar adecuadamente a los pacientes candidatos de NP es imprescindible para evitar complicaciones en pacientes subsidiarios de soporte nutricional enteral, menos agresivo y más fisiológico.\n---\nTema 48. Nutrición parenteral    775\n\nLa NP central permite un aporte de macronutrientes, micronutrientes y volumen ajustado a los requerimientos del paciente; esto no es posible en la NP con acceso periférico, en los que la composición de la NP va a estar condicionada por la osmolaridad de la solución.\n\nLos procesos de indicación, elaboración y administración de la NP deben realizarse cuidadosamente para conseguir el mayor beneficio clínico y evitar las complicaciones relacionadas con la NP.\n\nEn los últimos años, el desarrollo de nuevas emulsiones lipídicas, ha permitido minimizar las efectos nocivos de las primeras generaciones.\n\nAunque se necesita una mayor evidencia científica, la utilización de soluciones de AA específicas en pacientes con importante estrés catabólico, podrían aportar grandes beneficios en pacientes seleccionados.\n\nUna correcta monitorización de los pacientes con NP es fundamental para prevenir o detectar de manera precoz las complicaciones relacionadas con este tipo de soporte nutricional. Las complicaciones de la NP pueden condicionar el pronóstico de estos pacientes.\n\n## 9. Bibliografía\n\n1. Oliveira Fuster G., González Molero I. Nutrición Parenteral: Enfoque práctico para su prescripción y seguimiento. Oliveira Fuster G.Editor Manual de Nutrición Clínica y dietética, 2ª Edición. Madrid: Díaz de Santos; 2008. p. 233-255.\n2. SJ Dudrick Early developments and clinical applications of total parent\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>NUTRICIÓN PARENTERAL<|>EVENT<|>Nutrición parenteral (NP) is a medical treatment vital for patients with intestinal failure, providing essential nutrients intravenously to avoid complications associated with enteral nutrition.)\n##\n(\"entity\"<|>OLIVEIRA FUSTER G.<|>PERSON<|>Oliveira Fuster G. is an author who contributed to the literature on parenteral nutrition, focusing on its prescription and monitoring.)\n##\n(\"entity\"<|>SJ DUDRICK<|>PERSON<|>SJ Dudrick is a pioneer in the early developments and clinical applications of total parenteral nutrition.)\n##\n(\"entity\"<|>REINO UNIDO<|>GEO<|>The United Kingdom has transplant units that suggest criteria for considering intestinal or liver transplants in patients with portal hypertension, liver cirrhosis, or fibrosis.)\n##\n(\"entity\"<|>EMO<|>EVENT<|>Enfermedad metabólica ósea (EMO) is a condition observed in patients on prolonged parenteral nutrition, leading to osteoporosis and osteopenia.)\n##\n(\"entity\"<|>NUTRICIÓN PARENTERAL CENTRAL<|>EVENT<|>Central parenteral nutrition allows for the delivery of macronutrients and micronutrients tailored to patient needs, unlike peripheral parenteral nutrition.)\n##\n(\"entity\"<|>NUTRICIÓN PARENTERAL PERIFÉRICA<|>EVENT<|>Peripheral parenteral nutrition is limited by the osmolarity of the solution and does not provide the same benefits as central parenteral nutrition.)\n##\n(\"relationship\"<|>NUTRICIÓN PARENTERAL<|>EMO<|>Nutrición parenteral is associated with the development of metabolic bone disease (EMO) in patients on prolonged treatment<|>7)\n##\n(\"relationship\"<|>OLIVEIRA FUSTER G.<|>NUTRICIÓN PARENTERAL<|>Oliveira Fuster G. has written about the practical approach to the prescription and monitoring of parenteral nutrition<|>6)\n##\n(\"relationship\"<|>SJ DUDRICK<|>NUTRICIÓN PARENTERAL<|>SJ Dudrick is known for his early developments and clinical applications of total parenteral nutrition<|>8)\n##\n(\"relationship\"<|>REINO UNIDO<|>NUTRICIÓN PARENTERAL<|>The United Kingdom's transplant units provide guidelines for patients requiring parenteral nutrition<|>5)\n##\n(\"relationship\"<|>NUTRICIÓN PARENTERAL CENTRAL<|>NUTRICIÓN PARENTERAL<|>Central parenteral nutrition is a specific type of parenteral nutrition that offers tailored nutrient delivery<|>9)\n##\n(\"relationship\"<|>NUTRICIÓN PARENTERAL PERIFÉRICA<|>NUTRICIÓN PARENTERAL<|>Peripheral parenteral nutrition is a less effective form of parenteral nutrition compared to central parenteral nutrition<|>4)\n<|COMPLETE|>"}]}